Smoking worsens multiple sclerosis prognosis: two different pathways are involved

Area of Science:

• Immunology
• Neuroscience
• Toxicology

Background:

• Smoking is a known risk factor that exacerbates multiple sclerosis (MS) prognosis.
• The precise molecular mechanisms linking smoking to MS progression remain incompletely understood.

Purpose of the Study:

• To investigate the impact of smoking on specific molecular pathways in patients with multiple sclerosis.
• To elucidate the role of indoleamine 2,3-dioxygenase (IDO) activity and the renin-angiotensin system (RAS) in smoking-associated MS pathology.

Main Methods:

• Analysis of IDO activity and cytokine profiles (IL-6, IL-13, IL-17, IL-22) in MS patients who smoke.
• Assessment of RAS activity and chemokine production (CCL2, CCL3, CXCL10) by monocytes in smoking MS patients.
• Quantification of CD4+CD25+FoxP3+ regulatory T cells in relation to smoking status and pathway activity.

Main Results:

• Reduced IDO activity in smoking MS patients led to increased IL-6 and IL-13 production.
• Elevated RAS activity in smoking MS patients correlated with increased IL-17, IL-22, and chemokine production (CCL2, CCL3, CXCL10) from monocytes.
• Both pathways significantly decreased the number of CD4+CD25+FoxP3+ regulatory T cells in smoking MS patients.

Conclusions:

• Smoking-induced alterations in IDO activity and RAS contribute to immune dysregulation in MS.
• These molecular pathways may underlie the observed association between smoking and increased MS risk and severity.
• Targeting these pathways could offer novel therapeutic strategies for smoking MS patients.